Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...
All candidate predictors were obtained from the first clinical assessment within 6 hours after admission (first available values), including vital signs, GCS score, arterial blood gas parameters (PaO2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback